# US 2020/0002398 A1 · De Novo Design of Potent and Selective Interleukin Mimetics

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0002398 A1
- Document ID: US20200002398A1
- Status: Published application
- Kind: A1
- Application number: 16/572,038
- Filed: 2019-09-16
- Published: 2020-01-02
- Earliest claimed: 2018-06-25
- Assignees: University of Washington; The Board of Trustees of the Leland Stanford Junior University
- Applicants: University of Washington; The Board of Trustees of the Leland Stanford Junior University
- Inventors: Daniel Adriano SILVA MANZANO; Shawn YU; Umut ULGE; David BAKER; Kenan Christopher GARCIA; Jamie SPANGLER; Carl WALKEY; Alfredo QUIJANO RUBIO
- Web page: https://patentgrep.com/patent/US20200002398A1

## CPC

- C07K 14/55: IL-2
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K 47/62: the modifying agent being a protein, peptide or polyamino acid
- C07K 14/5406: {IL-4}
- C07K 14/5437: {IL-13}
- C07K 14/5443: {IL-15}
- C07K 14/7155: {for interleukins [IL]}
- C07K 16/246: {IL-2}
- G01N 33/6869: {Interleukin}
- G16B 15/20: Protein or domain folding
- G16B 15/30: Drug targeting using structural data; Docking or binding prediction
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C07K 2319/74: containing a fusion for binding to a cell surface receptor
- G01N 2333/5406: IL-4
- G01N 2333/55: IL-2
- G16B 50/30: Data warehousing; Computing architectures
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

De novo designed polypeptides that bind to IL-2 receptor βγcheterodimer (IL-2Rβγc), IL-4 receptor αγcheterodimer (IL-4Rαγc), or IL-13 receptor α subunit (IL-13Rα) are disclosed, as are methods for using and designing the polypeptides.

## Claims

### Claim at position 1

-138. (canceled)

### Claim 139

A non-naturally occurring polypeptide comprising domains X1, X2, X3, and X4, wherein:
(a) X1 is a peptide comprising the amino acid sequence at least 25%, 27%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 100% identical to EHALYDAL (SEQ ID NO:1);
(b) X2 is a helical-peptide of at least 8 amino acids in length;
(c) X3 is a peptide comprising the amino acid sequence at least 25%, 27%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 100% identical to YAFNFELI (SEQ ID NO:2);
(d) X4 is a peptide comprising the amino acid sequence at least 25%, 27%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 100% identical to ITILQSWIF (SEQ ID NO:3);
wherein X1, X2, X3, and X4 may be in any order in the polypeptide;
wherein amino acid linkers may be present between any of the domains; and
wherein the polypeptide binds to IL-2 receptor βγc heterodimer (IL-2Rβγc), IL-4 receptor αγcheterodimer (IL-4Rαγc), or IL-13 receptor α subunit (IL-13Rα).

### Claim 140 (depends on 139)

The polypeptide of claim 139 wherein the polypeptide binds to the IL-2 receptor βγc heterodimer (IL-2Rβγc).

### Claim 141 (depends on 139)

The polypeptide of claim 139 wherein the polypeptide binds to the IL-4 receptor αγcheterodimer (IL-4Rαγc), or IL-13 receptor α subunit (IL-13Rα)

### Claim 142 (depends on 140)

The polypeptide of claim 140, wherein:
(i) X1 includes one or both of the following: H at residue 2 and Y at residue 5; and/or
(ii) X3 includes 1, 2, 3, 4, or all 5 of the following: Y at residue 1, F at residue 3, N at residue 4, L at residue 7, and I at residue 8.

### Claim 143 (depends on 142)

The polypeptide of claim 142, wherein:
(iii) X4 includes I at residue 8.

### Claim 144 (depends on 141)

The polypeptide of claim 141, wherein:
(i) X1 includes E at residue 2 and K at residue 5; and
(ii) X3 includes F at residue 1, K at residue 3, R at residue 4, R at residue 7, and N at residue 8.

### Claim 145 (depends on 144)

The polypeptide of claim 144, wherein:
(iii) X4 includes F at residue 8.

### Claim 146 (depends on 139)

The polypeptide of claim 139, wherein:
X1 is a peptide comprising the amino acid sequence at least 25%, 27%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 100% identical along its length to the peptide PKKKIQLHAEHALYDALMILNI (SEQ ID NO: 4);
X3 is a peptide comprising the amino acid sequence at least 25%, 27%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 100% identical along its length the peptide LEDYAFNFELILEEIARLFESG (SEQ ID NO:5); and
X4 is a peptide comprising the amino acid sequence at least 25%, 27%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 100% identical along its length to the peptide EDEQEEMANAIITILQSWIFS (SEQ ID NO:6).

### Claim 147 (depends on 146)

The polypeptide of claim 146, wherein:
(i) X1 includes 1, 2, 3, 4, or all 5 of the following: L at residue 7, H at residue 8, H at residue 11, Yat residue 14; Mat residue 18; and/or
(ii) X3 includes 1, 2, 3, 4, 5, 6, 7, or all 8 of the following: D at residue 3, Y at residue 4, F at residue 6, N at residue 7, L at residue 10, I at residue 11, E at residue 13, or E at residue 14; and
(iii) X4 includes I at residue 19.

### Claim 148 (depends on 141)

The polypeptide of claim 141, wherein:
X1 is a peptide comprising the amino acid sequence at least 25%, 27%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 100% identical along its length to the peptide PKKKIQIMAEEALKDALSILNI (SEQ ID NO: 8);
X3 is a peptide comprising the amino acid sequence at least 37% 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 100% identical along its length the peptide LERFAKRFERNLWGIARLFESG (SEQ ID NO: 9); and
X4 is a peptide comprising the amino acid sequence at least 25%, 27%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 100% identical along its length to the peptide EDEQEEMANAIITILQSWFFS (SEQ ID NO: 10).
wherein
(i) X1 includes I at residue 7, T or M at residue 8, E at residue 11, K at residue 14 and S at residue 18; and
(ii) X3 includes R at residue 3, F at residue 4, K at residue 6, R at residue 7, R at residue 10, N at residue 11, W at residue 13, and G at residue 14.

### Claim 149 (depends on 148)

The polypeptide of claim 148, wherein
(iii) X4 includes F at residue 19.

### Claim 150 (depends on 139)

The polypeptide of claim 139, wherein the domains are arranged N-terminal to C-terminal in an arrangement selected from the group consisting of X1-X2-X3-X4; X1-X3-X2-X4; X1-X4-X2-X3; X3 -X2-X1-X4; X4-X3-X2-X1; X2-X3-X4-X1; and X2-X1-X4-X3.

### Claim 151 (depends on 146)

The polypeptide of claim 146, wherein:
amino acid residues relative to SEQ ID NO:4 are selected from the group consisting of:
Position 01:
A
F
I
L
M
P
Q
R
S
W
Position 02:
A
D
E
G
V
K
Position 03:
D
E
F
W
K
Position 04:
D
E
K
N
P
R
W
Position 05:
D
E
H
I
K
L
M
S
Position 06:
A
D
E
G
L
P
S
W
Q
Position 07:
D
E
L
Q
Y
I
Position 08:
A
F
H
W
Y
M
T
Position 09:
C
F
P
A
Position 10:
C
D
E
F
K
P
Position 11:
D
F
H
E
Position 12:
A
D
E
P
S
T
V
Position 13:
H
I
L
M
P
R
V
W
Position 14:
F
R
W
Y
K
Position 15:
D
E
N
Y
Position 16:
A
C
L
M
S
Position 17:
F
I
L
M
P
R
Position 18:
G
M
Q
Y
S
Position 19:
I
L
M
P
Q
V
Position 20:
A
K
L
M
Q
R
S
Position 21:
G
K
N
P
R
S
W
Position 22:
D
E
I
K
M
N
W
Y;
amino acid residues relative to SEQ ID NO:5 are selected from the group consisting of:
Position 01:
A
L
Position 02:
D
E
G
K
M
T
Position 03:
D
E
N
Y
R
Position 04:
C
D
G
T
Y
F
Position 05:
A
F
H
S
V
W
Y
Position 06:
A
F
I
M
T
V
Y
K
Position 07:
D
K
N
S
T
R
Position 08:
A
C
G
L
M
S
V
F
Position 09:
C
H
K
L
R
S
T
V
E
Position 10:
F
I
L
M
Y
R
Position 11:
I
L
N
T
Y
Position 12:
F
K
L
M
S
V
Position 13:
A
D
F
G
I
N
P
Q
S
T
E
W
Position 14:
A
E
F
G
H
S
V
Position 15:
C
I
L
M
V
W
Position 16:
A
D
G
S
T
V
Position 17:
H
K
L
N
R
Position 18:
C
D
G
I
L
Q
R
T
W
Position 19:
D
F
M
N
W
Position 20:
A
C
E
F
G
M
S
Y
Position 21:
D
E
G
H
L
M
R
S
T
V
W
Position 22:
A
D
G
K
N
S
Y;
and amino acid residues relative to SEQ ID NO:6 are selected from the group consisting of
Position 01:
D
E
G
K
V
Position 02:
D
I
M
S
Position 03:
E
G
H
K
Position 04:
E
G
I
K
Q
R
S
Position 05:
A
D
E
G
H
S
V
Position 06:
C
D
E
G
I
M
Q
R
T
V
Position 07:
C
E
L
M
P
R
T
Position 08:
A
F
L
M
W
Position 09:
A
G
L
N
Q
R
T
Position 10:
A
C
D
E
F
H
I
W
Position 11:
I
M
N
S
V
W
Position 12:
I
K
L
S
V
Position 13:
C
L
M
R
S
T
Position 14:
I
L
P
T
Y
Position 15:
F
G
I
L
M
N
V
Position 16:
H
K
Q
R
Position 17:
C
F
K
S
W
Y
Position 18:
K
Q
T
W
Position 19:
C
G
N
I
Position 20:
C
F
G
L
Y
Position 21:
A
F
G
H
S
Y

### Claim 152 (depends on 151)

The polypeptide of claim 151 comprising a cysteine substitution at position 3 relative to SEQ NO:6.

### Claim 153 (depends on 151)

The polypeptide of claim 151 comprising a cysteine substitution at position 17 or 20 relative to SEQ ID NO:5.

### Claim 154 (depends on 139)

The polypeptide of claim 139, wherein X2 is a peptide comprising the amino acid sequence at least 25%, 27%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 100% identical along its length to KDEAEKAKRMKEWMKRIKT (SEQ ID NO:7) .

### Claim 155 (depends on 154)

The polypeptide of claim 154, wherein amino acid residues relative to SEQ ID NO:7 are selected from the group consisting of:
Position 01:
A
H
L
M
R
S
V
K
Position 02:
A
D
E
Q
R
S
T
V
W
Y
Position 03:
C
E
G
K
L
N
Q
R
W
Position 04:
A
F
G
N
S
T
V
Y
Position 05:
A
E
G
I
M
R
V
C
Position 06:
C
E
K
L
N
R
V
Position 07:
A
C
E
I
L
S
T
V
W
Position 08:
H
K
L
M
S
T
W
Y
Position 09:
A
I
L
M
Q
S
R
Position 10:
A
I
M
S
W
Y
Position 11:
C
I
K
L
S
V
Position 12:
C
E
K
L
P
Q
R
T
Position 13:
A
D
H
N
W
Position 14:
A
C
G
I
L
S
T
V
M
Position 15:
A
E
G
I
K
L
M
R
V
Position 16:
G
H
L
R
S
T
V
C
Position 17:
A
I
L
V
Position 18:
A
C
D
E
G
H
I
K
M
S
Position 19:
D
E
G
L
N
V
T

### Claim 156 (depends on 155)

The polypeptide of claim 155 comprising a cysteine substitution at position 1, 2, 5, 9, 12, or 16 relative to SEQ NO:7.

### Claim 157 (depends on 139)

The polypeptide of claim 139, wherein the polypeptide comprises a polypeptide at least 25%, 27%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 100% identical to the amino acid sequence selected from the group consisting of SEQ ID NOS:11-94, 103-184, 190-243, and 245-247.

### Claim 158 (depends on 139)

The polypeptide of claim 139, wherein the polypeptide comprises a polypeptide at least 25%, 27%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 100% identical to the full length of the amino acid sequence of SEQ ID NO:90, and wherein one, two, or more of the following mutations are present:
R50C;
E53C;
E62C;
E69C;
R73C; and/or
E82C.

### Claim 159 (depends on 139)

The polypeptide of claim 139, wherein the polypeptide comprises a polypeptide at least 25%, 27%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 100% identical to the full length of the amino acid sequence of SEQ ID NO:181, and wherein one, two, or more of the following mutations are present
D56C;
K58C;
D59C;
R66C;
T77C;
E85C;
R50C;
E53C;
E62C;
E69C;
R73 C; and/or
E82C.

### Claim 160 (depends on 139)

The polypeptide of claim 139, wherein the polypeptide is linked to a stabilization compound, including but not limited to a polyethylene glycol (“PEG”) containing moiety.

### Claim 161 (depends on 160)

The polypeptide of claim 160, wherein the stabilization compound, including but not limited to a PEG-containing moiety, is linked at a cysteine residue in the polypeptide.

### Claim 162 (depends on 161)

The polypeptide of claim 161, wherein the cysteine residue is present in X2.

### Claim 163 (depends on 161)

The polypeptide of any one of claims 161, wherein the stabilization compound, including but not limited to a PEG-containing moiety, is linked to the cysteine reside via a maleimide group, including but not limited to linked to a cysteine residue present at amino acid residue 62 relative to SEQ ID NO:90.

### Claim 164 (depends on 139)

The polypeptide of claim 139, wherein the polypeptide includes at least one disulfide bond.

### Claim 165 (depends on 139)

The polypeptide of claim 139, wherein the polypeptide further comprises a targeting domain.

### Claim 166 (depends on 139)

A recombinant nucleic acid encoding the polypeptide of claim 139.

### Claim 167 (depends on 139)

A pharmaceutical composition comprising the polypeptide of claim 139.

### Claim 168 (depends on 139)

A method for treating cancer or for modulating an immune response comprising administering to a subject having cancer the polypeptide of claim 139.
